A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma

Multiple Myeloma Clinical Trial

Official title:

A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the FHND6091 in Subjects With Relapsed/Refractory Multiple Myeloma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05271682
• Other study ID #: LWY20071C
• Status: Recruiting
• Phase: Phase 1
• Start date: December 22, 2021
• Est. completion date: December 31, 2024

Study information

• Verified date: May 2023
• Source: Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
• Contact: Minghong Shang
• Phone: 025-57033246
• Email: shangmh[@]ctfh.com.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase I, first in human, single arm, open label study that will assess safety, tolerability and clinical activity of FHND6091 when taken orally on a weekly dosing schedule by patients with relapsed and refractory multiple myeloma (RRMM).The study will consist of two parts: dose escalation (Part 1) and dose expansion (Part 2).The dose escalation (Part 1) of the study will evaluate the safety and tolerability of FHND6091 using a dose escalation scheme to establish a maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). And the dose expansion (Part B) of the study will further evaluate the safety, pharmacokinetics (PK)/ pharmacodynamics (PD), and efficacy of FHND6091 at two selected dose levels to characterize the safety, tolerability and efficacy of FHND6091. A total of 40 evaluable participants will be enrolled in the study. The participants receiving treatment in part 1 and part 2 may continue combination treatment for a total of up to 12 cycles. After 12 cycles of therapy, the participants will continue treatment until the occurrence of PD, intolerable AEs, consent withdrawal, death or end of study based on the judgement of investigator's assessment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients must give written informed consent.
• Male or female patients 18 years or older.
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2.
• Life expectancy of at least 12 weeks.
• Patients with multiple myeloma who have relapsed or refractory, intolerance or refuse treatment following at least 3 regimens or lines of therapy that must include an IMID (lenalidomide or thalidomide), a proteasome inhibitor (bortezomib) , a CD38-targeted mAbs and corticosteroids. Patients must have received transplant therapy or are not suitable for transplant.
• For Patients With Relapsed Refractory Multiple Myeloma must have measurable disease defined by at least 1 of the following 2 measurements: Serum M-protein = 5 g/L, or Urine M-protein = 200 mg/24 hours. For patients with serum free light chain as measurable disease: Serum immunoglobulin free light chain =10 mg/dL and abnormal serum immunoglobulin kappa to lambda free light chain ratio.
• Clinical laboratory values as specified below within 14 days before the first dose of

study drug:

1. Hemoglobin = 75 g/L, Absolute neutrophil count = 1.0 x 10E9/L and Platelet count = 75 x 10E9/L without blood transfusion, EPO or G-CSF and other medical support for at least 14 days prior to receiving screening.

2. Total bilirubin levels = 2 x ULN, AST (SGOT) and ALT (SGPT) = 2 x ULN.

3. Calculated or measured creatinine clearance (CrCl) of = 30 mL/minute as calculated by Cockcroft-Gault method.

4. Corrected Serum Calcium = ULN.

• For man and women of childbearing potential: agreement to remain abstinent or use contraception, during the treatment period (including treatment interruptions) and for at least 180 days after the last dose of FHND6091 was administered. Women of childbearing potential should be negative by serum pregnancy test within 7 days prior dosing.

Exclusion Criteria:

• Documented allergy to proteasome inhibitor or ;
• Patients with peripheral neuropathy = Grade 2 or Grade 1 peripheral neuropathy with pain.
• Patients with diarrhea > Grade 1 (Increase of <4 stools per day over baseline; mild increase in ostomy output compared to baseline).
• Patients received chemotherapy, radiation therapy, targeted therapy, immunotherapy or other systemic anticancer therapy within 14 days prior FHND6091 treatment.
• Patients received ixazomib treatment within 5 elimination half-life prior first dose of FHND6091 treatment.
• Patients received allogeneic stem cell transplantation or autologous stem cell transplant with 12 weeks before screening.
• Patients with symptomatic brain metastases, leptomeningeal metastases or, spinal cord compression or central nervous system (CNS) injuries/abnormalities based on investigator judgement.
• Evidence of severe or uncontrolled systemic diseases (eg, unstable or uncompensated respiratory, hepatic or renal disease), or receive major surgery.
• Patients with unstable hypertension after drug treatment (SBP =140 mmHg, DBP =90 mmHg ) or heart failure, myocardial ischemia or myocardial infarction, unstable angina, arrhythmia (The corrected QT interval (Fridericia formula) interval (QTcF) > 470 msec for females and > 450 msec for men in electrocardiogram (ECG)).
• Patients with active, or a history of immunodeficiency, including HIV positive or other acquired and congenital immunodeficiency diseases, or a history of solid organ transplant.
• Patients with a history of other serious underlying diseases, such as: a, history of a clear neurological or psychiatric disorder, including epilepsy or dementia. b, HBV surface antigen positivity (subjects with documented laboratory evidence of HBV clearance may be enrolled) or positive HCV antibody. c, presence of infection requiring systemic treatment.
• Systemic treatment with strong inhibitors of of CYP3A4 or strong CYP3A4 inducers within 5 elimination half-life prior first dose of FHND6091 treatment.
• Patients have not recovered (ie, = Grade 1 toxicity by CTCAE 5.0) from the reversible effects of prior antineoplastic therapy (except for alopecia )
• Patients with other malignancy;
• Treatment with any investigational products within 28 days before the first dose of study treatment

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• FHND6091
FHND6091 capsules

Locations

Country	Name	City	State
China	The first affiliated hospital of bengbu medical college	Bengbu	Anhui
China	The Third Hosptial of Changsha	Changsha	Hunan
China	Ruijin Hospital	Shanghai
China	Xi'an Central Hospital	Xi'an	Shaanxi
China	The Affilitated Hospital of Xuzhou Medical University	Xuzhou	Jiangsu
China	Henan Cancer Hospital	Zhengzhou	Henan

Sponsors (1)

Lead Sponsor	Collaborator
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants Reporting One or More Treatment-Emergent Adverse Events and Serious Adverse Events	An Adverse Event is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.; A Serious Adverse Event (SAE) was any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.	Baseline to 28 days after first dose of FHND6091 administration
Secondary	Complete Response/Stringent Complete Response (CR/sCR) Rate	CR/sCR to FHND6091, according to international myeloma working group (IMWG) criteria	Baseline to 12 months after first dose of FHND6091 administration
Secondary	Rate of Very Good Partial Response (VGPR) or Better	VGPR to FHND6091, according to international myeloma working group (IMWG) criteria	Baseline to 12 months after first dose of FHND6091 administration
Secondary	Partial Response (PR)	PR to FHND6091, according to international myeloma working group (IMWG) criteria	Baseline to 12 months after first dose of FHND6091 administration
Secondary	Cmax: Maximum Observed Plasma Concentration for FHND6091	Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve for FHND6091	Days 1 and 15 of Cycle 1 (each cycle is 28 days)
Secondary	Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for FHND6091	Time to reach the maximum observed plasma concentration (Cmax), equal to time to Cmax	Days 1 and 15 of Cycle 1 (each cycle is 28 days)
Secondary	AUC(0-168): Area Under the Plasma Concentration-Time Curve From Time 0 to 168 Hours Postdose for FHND6091	AUC(0-168) is a measure of the area under the plasma concentration-time curve over the dosing interval (tau) (AUC[0-tau]), where tau is the length of the dosing interval - 168 hours in this study)	Days 1 and 15 of Cycle 1 (each cycle is 28 days)